thiazoles has been researched along with Dyslipidemia in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (33.33) | 29.6817 |
| 2010's | 10 (55.56) | 24.3611 |
| 2020's | 2 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Gao, Y; Guo, S; Shi, Y; Yang, L; Ye, L; Zhang, T; Zhao, T; Zheng, Y; Zhou, L | 1 |
| Banks, CD; Deeter, J; Langley, P; Rollins, MR | 1 |
| Amersfoort, J; Bot, I; Chi, H; Douna, H; Foks, AC; Hankemeier, T; Harms, A; Kuiper, J; Moreno-Gordaliza, E; Schaftenaar, FH; Slütter, B; van Puijvelde, GHM; van Santbrink, PJ; Wang, Y | 1 |
| Arco, R; Baixeras, E; Decara, J; Gavito, A; Lopez-Gambero, AJ; Martínez, A; Navarro, JA; Pavón, FJ; Rivera, P; Rodríguez de Fonseca, F; Serrano, A; Suárez, J; Tovar, R; Vargas, A | 1 |
| Bojic, LA; Huff, MW | 1 |
| Bahk, WM; Kim, MD; Kwon, YJ; Lee, HB; Lee, JG; Woo, YS; Yoon, BH | 1 |
| Bojic, LA; Burke, AC; Chhoker, SS; Edwards, JY; Huff, MW; Pickering, JG; Sawyez, CG; Sutherland, BG; Telford, DE; Tirona, RG; Yin, H | 1 |
| Chew, GT; Sahebkar, A; Watts, GF | 1 |
| Banach, M; Castellino, G; Ivanova, E; Montalto, G; Nikolic, D; Orekhov, AN; Rizzo, M; Toth, PP | 1 |
| Chen, W; Li, S; Liu, HY; Long, L; Wang, LL | 1 |
| Billin, AN | 1 |
| Barrett, PH; Chan, DC; Ooi, EM; Sprecher, DL; Watts, GF | 1 |
| Bobo, WV; Chen, Y; Jayathilake, K; Meltzer, HY; Tang, T; Watts, K | 1 |
| Jones, NP; Olson, EJ; Pearce, GL; Sprecher, DL | 1 |
| Beneton, V; Boullay, AB; Boyer, T; Brewster, AG; Donche, F; Forest, MC; Fouchet, MH; Gellibert, FJ; Grillot, DA; Lambert, MH; Laroze, A; Le Grumelec, C; Linget, JM; Montana, VG; Nguyen, VL; Nicodème, E; Patel, V; Penfornis, A; Pianetti, PM; Pineau, O; Pohin, D; Potvain, F; Poulain, G; Ruault, CB; Saunders, M; Sierra, ML; Toum, J; Xu, HE; Xu, RX | 1 |
| Wooten, J | 1 |
| Perlis, RH | 1 |
| D'Agostino, RB; Eng, SM; Faich, GA; Kane, JM; Reynolds, RF; Ruskin, JN; Strom, BL | 1 |
7 review(s) available for thiazoles and Dyslipidemia
| Article | Year |
|---|---|
Peroxisome proliferator-activated receptor δ: a multifaceted metabolic player.
Topics: Animals; Anti-Inflammatory Agents; Atherosclerosis; Clinical Trials as Topic; Dyslipidemias; Hepatocytes; Humans; Inflammation; Insulin Resistance; Liver; Macrophages; Mice; PPAR delta; Thiazoles | 2013 |
The efficacy and safety of switching to ziprasidone from olanzapine in patients with bipolar I disorder: an 8-week, multicenter, open-label study.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Drug Substitution; Drug Therapy, Combination; Dyslipidemias; Female; Humans; Lithium; Male; Middle Aged; Olanzapine; Piperazines; Prospective Studies; Thiazoles; Treatment Outcome; Valproic Acid; Young Adult | 2013 |
New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease.
Topics: Acetates; Animals; Atherosclerosis; Chalcones; Cholesterol, HDL; Dyslipidemias; Fatty Liver; Fenofibrate; Humans; Insulin Resistance; Lipoproteins, HDL; Non-alcoholic Fatty Liver Disease; Peroxisome Proliferator-Activated Receptors; Propionates; Quinolines; Sulfonamides; Thiazoles; Triazoles; Triglycerides | 2014 |
PPAR Agonists, Atherogenic Dyslipidemia and Cardiovascular Risk.
Topics: Animals; Atherosclerosis; Cardiovascular Diseases; Clinical Trials as Topic; Dyslipidemias; Humans; Hypolipidemic Agents; Peroxisome Proliferator-Activated Receptors; Risk Factors; Thiazoles | 2017 |
PPAR-beta/delta agonists for Type 2 diabetes and dyslipidemia: an adopted orphan still looking for a home.
Topics: Animals; Atherosclerosis; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dyslipidemias; Glucose; Humans; Insulin Resistance; Lipoproteins; PPAR delta; PPAR-beta; Propionates; Thiazoles | 2008 |
Metabolic effects of the atypical antipsychotics.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Diabetes Mellitus; Dibenzothiazepines; Dyslipidemias; Glucose Metabolism Disorders; Humans; Insulin Resistance; Mental Disorders; Obesity; Olanzapine; Phenothiazines; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Thiazoles | 2007 |
Treatment of bipolar disorder: the evolving role of atypical antipsychotics.
Topics: Antipsychotic Agents; Aripiprazole; Arrhythmias, Cardiac; Benzodiazepines; Bipolar Disorder; Diabetes Mellitus, Type 2; Dibenzothiazepines; Drug Evaluation; Drug Interactions; Drug Therapy, Combination; Dyslipidemias; Humans; Hyperprolactinemia; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Thiazoles; Treatment Outcome; Weight Gain | 2007 |
4 trial(s) available for thiazoles and Dyslipidemia
| Article | Year |
|---|---|
Mechanism of action of a peroxisome proliferator-activated receptor (PPAR)-delta agonist on lipoprotein metabolism in dyslipidemic subjects with central obesity.
Topics: Adult; Apolipoprotein A-I; Apolipoprotein A-II; Apolipoproteins B; Apolipoproteins C; Cholesterol; Cross-Over Studies; Double-Blind Method; Dyslipidemias; Humans; Kinetics; Lipids; Lipoproteins; Lipoproteins, HDL; Lipoproteins, LDL; Lipoproteins, VLDL; Male; Middle Aged; Obesity, Abdominal; PPAR delta; Thiazoles; Triglycerides | 2011 |
Comparative effectiveness of switching antipsychotic drug treatment to aripiprazole or ziprasidone for improving metabolic profile and atherogenic dyslipidemia: a 12-month, prospective, open-label study.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Atherosclerosis; Bipolar Disorder; Cohort Studies; Diagnostic and Statistical Manual of Mental Disorders; Drug Monitoring; Dyslipidemias; Female; Humans; Intention to Treat Analysis; Male; Middle Aged; North America; Patient Dropouts; Piperazines; Psychotic Disorders; Quinolones; Risk Factors; Schizophrenia; Severity of Illness Index; Thiazoles; Weight Loss | 2012 |
Lipid effects of peroxisome proliferator-activated receptor-δ agonist GW501516 in subjects with low high-density lipoprotein cholesterol: characteristics of metabolic syndrome.
Topics: Adult; Analysis of Variance; Apolipoprotein A-I; Apolipoproteins B; Biomarkers; Blood Glucose; Chi-Square Distribution; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Double-Blind Method; Dyslipidemias; Fatty Acids, Nonesterified; Female; Humans; Hypolipidemic Agents; Insulin; Male; Metabolic Syndrome; Middle Aged; PPAR gamma; Thiazoles; Time Factors; Treatment Outcome; Triglycerides | 2012 |
The Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC): design and baseline subject characteristics.
Topics: Adult; Antipsychotic Agents; Body Mass Index; Dyslipidemias; Female; Glycated Hemoglobin; Humans; Hypertension; Long QT Syndrome; Male; Observation; Piperazines; Prevalence; Research Design; Schizophrenia; Severity of Illness Index; Surveys and Questionnaires; Thiazoles; Triglycerides | 2008 |
7 other study(ies) available for thiazoles and Dyslipidemia
| Article | Year |
|---|---|
Exposure to PM
Topics: Animals; Asthma; Cholesterol, HDL; Cholesterol, LDL; Diamines; Disease Models, Animal; Dyslipidemias; Female; Gene Expression; Lipid Metabolism; Male; Ovalbumin; Particulate Matter; Rats; Rats, Wistar; Signal Transduction; Thiazoles; Transcription Factor HES-1; Triglycerides | 2019 |
New onset metabolic derangement in a pediatric patient receiving therapeutic plasma exchange for anti-NMDA receptor encephalitis.
Topics: Anti-N-Methyl-D-Aspartate Receptor Encephalitis; Antipsychotic Agents; Child; Dyslipidemias; Female; Humans; Piperazines; Plasma Exchange; Plasmapheresis; Receptors, N-Methyl-D-Aspartate; Thiazoles | 2020 |
Diet-induced dyslipidemia induces metabolic and migratory adaptations in regulatory T cells.
Topics: Animals; Atherosclerosis; Cell Movement; Cells, Cultured; Coculture Techniques; Diet, High-Fat; Disease Models, Animal; Dyslipidemias; Energy Metabolism; Fatty Acids; Inflammation; Inflammation Mediators; Mechanistic Target of Rapamycin Complex 1; Mechanistic Target of Rapamycin Complex 2; Mice, Knockout, ApoE; Oxidation-Reduction; Phenotype; Plaque, Atherosclerotic; PPAR gamma; Receptors, LDL; Signal Transduction; T-Lymphocytes, Regulatory; Thiazoles | 2021 |
The adiponectin promoter activator NP-1 induces high levels of circulating TNFα and weight loss in obese (fa/fa) Zucker rats.
Topics: Adiponectin; Adipose Tissue, Brown; Animals; Body Weight; DNA (Cytosine-5-)-Methyltransferase 1; Dyslipidemias; Feeding Behavior; Gene Expression Regulation; Hypothalamus; Liver; Male; Obesity; Promoter Regions, Genetic; Rats; Rats, Zucker; Thiazoles; Thinness; Tumor Necrosis Factor-alpha; Weight Loss | 2018 |
Peroxisome proliferator-activated receptor δ agonist GW1516 attenuates diet-induced aortic inflammation, insulin resistance, and atherosclerosis in low-density lipoprotein receptor knockout mice.
Topics: Animals; Anti-Inflammatory Agents; Aortitis; Atherosclerosis; Biomarkers; Blood Glucose; Cholesterol, Dietary; Diet, High-Fat; Disease Models, Animal; Dyslipidemias; Inflammation Mediators; Insulin; Insulin Resistance; Lipids; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; PPAR delta; Receptors, LDL; Signal Transduction; Thiazoles; Time Factors | 2014 |
Peroxisome proliferator-activated receptor delta-agonist, GW501516, ameliorates insulin resistance, improves dyslipidaemia in monosodium L-glutamate metabolic syndrome mice.
Topics: Animals; Animals, Newborn; Blood Glucose; Cholesterol, HDL; Dyslipidemias; Fatty Acids; Gene Expression; Insulin; Insulin Resistance; Leptin; Metabolic Syndrome; Mice; Mice, Obese; Oxidation-Reduction; PPAR delta; Sodium Glutamate; Thiazoles | 2008 |
Substituted 2-[(4-aminomethyl)phenoxy]-2-methylpropionic acid PPARalpha agonists. 1. Discovery of a novel series of potent HDLc raising agents.
Topics: Animals; Apolipoprotein A-I; Cholesterol, HDL; Cholesterol, VLDL; Crystallography, X-Ray; Dogs; Dyslipidemias; Humans; Ligands; Mice; Mice, Inbred C57BL; Mice, Transgenic; Models, Molecular; PPAR alpha; Propionates; Protein Structure, Tertiary; Rats; Rats, Wistar; Structure-Activity Relationship; Thiazoles; Triglycerides | 2007 |